[{"data":1,"prerenderedAt":65},["ShallowReactive",2],{"q-nurse-106-2-medical-surgical-059":3},{"subject":4,"subjectSlug":5,"subjectFullName":4,"question":6,"related":34,"lastmod":64},"內外科護理學","medical-surgical",{"id":7,"webId":8,"year":9,"session":10,"subject":4,"number":11,"stem":12,"options":13,"answer":18,"answerNote":19,"images":20,"explanation":21,"explanationDeep":22,"topics":23,"freq":26},"nurse-106-2-內外科護理學-059","nurse-106-2-medical-surgical-059",106,2,59,"下列何種藥物可以直接灌注於膀胱內以治療膀胱癌？",{"A":14,"B":15,"C":16,"D":17},"BCG","cisplatin","methotrexate","vinblastine","A",null,[],"本題考點為膀胱癌的膀胱內灌注治療藥物。卡介苗(BCG)灌注入膀胱可刺激局部免疫反應對抗表淺性膀胱癌(非肌肉侵犯型),是標準的膀胱內免疫治療,故 A 正確。B cisplatin、C methotrexate、D vinblastine 皆為全身性化療藥(常組成 M-VAC 方案用於侵犯性或轉移性膀胱癌的靜脈化療),並非直接灌注膀胱的局部治療藥。膀胱內灌注以 BCG 為代表,故選 A。","表淺性膀胱癌(尤其原位癌 CIS 與高風險非肌肉侵犯)標準輔助治療為經尿道切除後行『膀胱內 BCG 灌注』,機轉是誘發局部 T 細胞媒介免疫反應;灌注後需憋尿約 2 小時並定期轉換體位讓藥液接觸各壁。全身化療(cisplatin 為主的 M-VAC\u002FGC)保留給侵犯性或轉移病灶。口訣:『表淺膀胱癌→BCG 灌;侵犯轉移→cisplatin 化療』。",[24,27,30,32],{"term":25,"count":26},"膀胱癌",7,{"term":28,"count":29},"卡介苗(BCG)膀胱內灌注",1,{"term":31,"count":29},"免疫治療",{"term":33,"count":29},"M-VAC 全身化療",[35,39,44,49,54,59],{"webId":36,"stem":37,"number":38,"year":9,"session":10},"nurse-106-2-medical-surgical-060","與尿液 pH 值無關之尿路結石成分，下列何者正確？",60,{"webId":40,"stem":41,"number":42,"year":43,"session":29},"nurse-107-1-medical-surgical-076","中毒病人最優先之處置原則，下列何者正確？",76,107,{"webId":45,"stem":46,"number":47,"year":48,"session":29},"nurse-108-1-medical-surgical-010","有關口腔癌之敘述，下列何者錯誤？",10,108,{"webId":50,"stem":51,"number":52,"year":53,"session":29},"nurse-109-1-medical-surgical-048","有關肺栓塞病人之護理處置，下列敘述何者最正確？",48,109,{"webId":55,"stem":56,"number":57,"year":58,"session":10},"nurse-110-2-medical-surgical-012","有關內視鏡逆行膽胰攝影的敘述，下列何者正確？",12,110,{"webId":60,"stem":61,"number":62,"year":63,"session":10},"nurse-111-2-medical-surgical-046","有關皮膚惡性腫瘤病人的護理措施，下列何者錯誤？",46,111,"2026-09-04",1788510698809]